Allergan stock looks attractive – Barron’s

NEW YORK, May 16 (BestGrowthStock) – Allergan Inc (AGN.N: ), the
maker of Botox, is set to reap the rewards of an aging
population, financial weekly Barron’s said in its May 17
edition.

Allergan’s stock trade at around $61 — 17 times projected
2011 profits. Drug companies sell for 10 times earnings, but
cannot match Allergan’s 19 percent profit margins, according to
Barron’s.

Allergan bought the rights to Botox in 1988 for $9 million.
Today it is worth $1.3 billion, and this could grow if
regulators approve the product for treating migraine headaches.
Wells Fargo said there was a 60 percent chance regulators would
approve it in July, Barron’s said.

The company also produces skin-care treatments, which saw a
32 percent boost in sales during the first quarter of 2010.

Stock Market News

(Reporting by Helen Kearney, editing by Maureen Bavdek)

Allergan stock looks attractive – Barron’s